F1 Oncology, Inc., a West Palm Beach, Fla.-based biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, received a $10m equity investment.
Backers included current investors which provided the funding upon ethics committee approval of a novel precision medicine-directed trial sponsored by Shanghai Sinobioway Sunterra Biotechnology and its hospital collaborators for two novel chimeric antigen receptor T cell (CAR-T) products for the treatment of metastatic renal cell carcinoma (mRCC).
Formed in November 2015 and led by Gregory Frost, Ph.D. Chairman & CEO, F1 Oncology leverages its globally integrated science, development and informatics teams located across multiple time zones to accelerate the design, high-throughput screening, discovery and development of adoptive cellular therapy (ACT) candidates. The company is developing two CAB-based ACT platforms to develop TME-restricted CAR-T therapies for solid tumors, as well as developing highly scalable systems for global deployment, beginning in Asia.
F1 Oncology is a private Delaware corporation with operations in West Palm Beach, Florida, San Diego, California and international affiliates in George Town, Cayman Islands, Hong Kong, and Shanghai, China.